June 26, 2009
European CHMP Adopts Positive Opinion for Aztreonam Lysine

June 18, 2009
Gilead Sciences to Present at the Piper Jaffray 4th Annual Europe Conference on Wednesday, June 24

June 2, 2009
Gilead Sciences to Present at Two Upcoming Investor Conferences

May 28, 2009
Gilead Sciences' Marketing Authorisation Application for Regadenoson Validated by European Medicines Agency

May 22, 2009
Gilead Sciences Announces Changes to Cardiovascular R & D Organization Leadership

May 18, 2009
New Data for Gilead Sciences' Ambrisentan Show Clinical Improvements in a Diverse Pulmonary Hypertension (PH) Population

May 15, 2009
Gilead Sciences to Present at the Deutsche Bank 34th Annual Healthcare Conference on Tuesday, May 19

May 14, 2009
Gilead Sciences Files Second Patent Infringement Lawsuit Against Teva Pharmaceuticals

May 12, 2009
Gilead Palo Alto, Inc. Announces Tender Offer for Convertible Notes

May 8, 2009
Gilead Sciences' Phase III Darusentan Data Show Significant Blood Pressure Reductions in Resistant Hypertension Patients

April 21, 2009
Gilead Sciences Announces Record First Quarter 2009 Financial Results

April 17, 2009
Gilead Sciences Completes Acquisition of CV Therapeutics

April 17, 2009
Gilead Initiates Phase II Clinical Trial of Integrase-Based, Single-Tablet, Once-Daily Regimen for the Treatment of HIV

April 15, 2009
Gilead Sciences Successfully Completes Tender Offer for Shares of CV Therapeutics With Over 88 Percent of Shares Tendered

April 14, 2009
Gilead Sciences to Release First Quarter 2009 Financial Results on Tuesday, April 21, 2009

April 13, 2009
Phase III Data for Gilead Sciences' Darusentan Accepted as Late-Breaker Presentation at ASH 2009

April 6, 2009
Gilead Sciences Announces Notification of ANDA Filing for
Atripla(R)

April 2, 2009
Phase III Study of Gilead's Darusentan for Resistant Hypertension Meets Primary Endpoints

March 31, 2009
Gilead Sciences Announces Early Termination of Hart-Scott-Rodino Waiting Period

March 24, 2009
Gilead Initiates Phase II Clinical Trial of Cicletanine for the Treatment of Pulmonary Arterial Hypertension

March 19, 2009
European CHMP Adopts Negative Opinion on Aztreonam Lysine

March 13, 2009
Department of Justice Declines to Intervene in False Claims Act Lawsuits Against Gilead Sciences

March 12, 2009
Gilead Sciences Agrees to Acquire CV Therapeutics for $20.00 Per Share

March 11, 2009
Gilead Sciences to Present at the Cowen and Company 29th Annual Healthcare Conference on Monday, March 16

March 6, 2009
Gilead Sciences to Present at the Barclays Capital Global Healthcare Conference on Tuesday, March 10

February 18, 2009
Gilead Receives Response From U.S. FDA on Company's Request for Formal Dispute Resolution for Aztreonam for Inhalation Solution

February 9, 2009
Gilead Announces Data Demonstrating Pharmacokinetic Boosting Activity of GS 9350

February 6, 2009
Gilead Sciences to Present at the 11th Annual BIO CEO Investor Conference on Tuesday, February 10

February 2, 2009
Gilead Announces Senior Management Promotion

January 29, 2009
Gilead Completes Acquisition of Building and Associated Land from EFI

January 27, 2009
Gilead Outlines R & D Priorities for 2009

January 27, 2009
Gilead Sciences Announces Record Fourth Quarter and Full Year 2008 Financial Results

January 16, 2009
Gilead Sciences to Release Fourth Quarter and Year End 2008 Financial Results on Tuesday, January 27, 2009

January 7, 2009
Gilead Sciences to Present at the 27th Annual JPMorgan Healthcare Conference on Monday, January 12